Sensei Biotherapeutics (NASDAQ:FTH) Upgraded at Robert W. Baird

Sensei Biotherapeutics (NASDAQ:FTH) was upgraded by equities research analysts at Robert W. Baird to a “strong-buy” rating in a report issued on Thursday,Zacks.com reports.

A number of other equities research analysts have also issued reports on FTH. Weiss Ratings began coverage on shares of Sensei Biotherapeutics in a research note on Wednesday, June 17th. They set a “sell (d-)” rating for the company. HC Wainwright started coverage on shares of Sensei Biotherapeutics in a research note on Monday, June 22nd. They issued a “buy” rating and a $60.00 price target on the stock. Finally, BTIG Research upgraded Sensei Biotherapeutics to a “strong-buy” rating in a report on Thursday, June 11th. Two analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $58.50.

Sensei Biotherapeutics Trading Down 7.3%

Sensei Biotherapeutics stock opened at $22.87 on Thursday. The company has a market capitalization of $30.69 million, a price-to-earnings ratio of -0.16 and a beta of -0.25. Sensei Biotherapeutics has a twelve month low of $6.32 and a twelve month high of $36.76.

Insiders Place Their Bets

In other news, CEO Anand Kiran Parikh purchased 2,806 shares of the firm’s stock in a transaction on Monday, June 22nd. The stock was bought at an average cost of $19.76 per share, for a total transaction of $55,446.56. Following the completion of the acquisition, the chief executive officer directly owned 764,234 shares of the company’s stock, valued at approximately $15,101,263.84. The trade was a 0.37% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Brian C. Stephenson purchased 9,391 shares of the stock in a transaction dated Wednesday, June 24th. The stock was acquired at an average cost of $26.13 per share, for a total transaction of $245,386.83. Following the completion of the transaction, the chief financial officer owned 26,804 shares of the company’s stock, valued at $700,388.52. The trade was a 53.93% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have acquired 35,860 shares of company stock valued at $862,703. Company insiders own 7.00% of the company’s stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.